High interstitial fluid pressure - An obstacle in cancer therapy

Nature Reviews Cancer

Volumn 4, Issue 10, 2004, Pages 806-813

  Heldin, Carl Henrik ^a   Rubin, Kristofer ^b   Pietras, Kristian ^c   Östman, Arne ^d  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; BRADYKININ RECEPTOR AGONIST; CARBOPLATIN; COLLAGEN; DEXAMETHASONE; GLUCOSE; HYALURONIC ACID; HYALURONIDASE; IMATINIB; INTEGRIN; IRINOTECAN; LOBRADIMIL; NICOTINAMIDE; OXYGEN; PHOSPHOLIPASE A2; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTAGLANDIN E1; PROTEIN; PROTEIN INHIBITOR; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

CANCER RECURRENCE; CAPILLARY FLOW; DRUG EFFICACY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; HUMAN; MOLECULAR WEIGHT; NONHUMAN; OSMOTIC PRESSURE; PRESSURE GRADIENT; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TECHNIQUE; TISSUE PRESSURE; TRANSPORT KINETICS; TUMOR VASCULARIZATION;

ALPROSTADIL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BRADYKININ; EXTRACELLULAR FLUID; HUMANS; HYALURONOGLUCOSAMINIDASE; HYDROSTATIC PRESSURE; MICE; NEOPLASMS; NIACINAMIDE; PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4944266313     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1456     Document Type: Review

References (75)

1. Young, J. S. et al. The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J. Pathol. Bacteriol. 62, 313-333 (1950).
2. Jain, R. K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6, 559-593 (1987).
3. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 47, 3039-3051 (1987). References 2 and 3 were the first to propose that the increased IFP of some tumours is a barrier to drug delivery.
4. Less, J. R. et al. Interstitial hypertension in human breast and colorectal tumors. Cancer Res. 52, 6371-6374 (1992).
5. Nathanson, S. D. et al. Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. Ann. Surg. Oncol. 1, 333-338 (1994).
6. Curti, B. D. et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 53, 2204-2207 (1993).
7. Boucher, Y. et al. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 51, 6691-6694 (1991).
8. Gutmann, R. et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 52, 1993-1995 (1992).
9. Jain, R. K. The next frontier of molecular medicine: delivery of therapeutics. Nature Med. 4, 655-657 (1998).
10. Jain, R. K. Barriers to drug delivery in solid tumors. Sci. Am. 271, 58-65 (1994).
11. Boucher, Y. et al. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50, 4478-4484 (1990).
12. DiResta, G. R. et al. Characterization of neuroblastoma xenograft in rat flank. I. Growth, interstitial fluid pressure, and interstitial fluid velocity distribution profiles. Microvasc. Res. 46, 158-177 (1993).
13. Rippe, B. et al. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol. Rev. 74, 163-219 (1994).
14. Roh, H. D. et al. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res. 51, 6695-6698 (1991).
15. Milosevic, M. et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 61, 6400-6405 (2001).
16. Aukland, K. et al. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol. Rev. 73, 1-78 (1993). A thorough and complete review of the mechanisms that control extracellular fluid flow and interstitial fluid pressure.
17. Chary, S. R. et al. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc. Natl Acad. Sci. USA 86, 5385-5389 (1989).
18. Lund, T. et al. Acute postburn edema: role of strongly negative interstitial fluid pressure. Am. J. Physiol. 255, H1069-H1074 (1988).
19. Wiig, H. et al. New and active role of the interstitium in control of interstitial fluid pressure: potential therapeutic consequences. Acta Anaesthesiol. Scand. 47, 111-121 (2003).
20. Reed, R. K. et al. Control of interstitial fluid pressure: role of β1-integrins. Semin. Nephrol. 21, 222-230 (2001).
21. Meyer, F. A. Macromolecular basis of globular protein exclusion and of swelling pressure in loose connective tissue (umbilical cord). Biochim. Biophys. Acta 755, 388-399 (1983).
22. Steinberg, B. M. et al. Establishment and transformation diminish the ability of fibroblasts to contract a native collagen gel. J. Cell Biol. 87, 304-308 (1980).
23. Clark, R. A. F. et al. Platelet isoforms of platelet-derived growth factor stimulate fibroblasts to contract collagen matrices. J. Clin. Invest. 84, 1036-1040 (1989).
24. 1 Integrin-mediated collagen gel contraction is stimulated by PDGF. Exp. Cell Res. 186, 264-272 (1990).
25. Montesano, R. et al. Transforming growth factor β stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc. Natl Acad. Sci. USA 85, 4894-4897 (1988).
26. Grundstrom, G. et al. Integrin αvβ3 mediates platelet-derived growth factor-BB-stimulated collagen gel contraction in cells expressing signaling deficient integrin α2β1. Exp. Cell Res. 291, 463-473 (2003).
27. Reed, R. K. et al. Blockade of β1-integrins in skin causes edema through lowering of interstitial fluid pressure. Circ. Res. 71, 978-983 (1992).
28. Rodt, S. Å. et al. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J. Physiol. 495, 193-200 (1996). Demonstration that PDGF-BB controls the IFP of normal tissue.
29. Heuchel, R. et al. Platelet-derived growth factor β receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc. Natl Acad. Sci. USA 96, 11410-11415 (1999).
30. Wennström, S. et al. Membrane ruffling and chemotaxis transduced by the PDGFβ-receptor require the binding site for phosphatidylinositol 3′ kinase. Oncogene 9, 651-660 (1994).
31. Berg, A. et al. Cytochalasin D induces edema formation and lowering of interstitial fluid pressure in rat dermis. Am. J. Physiol. Heart Circ. Physiol. 281, H7-H13 (2001).
32. 2 alpha; analogs on collagen gel compaction in vitro and interstitial pressure in vivo. Am. J. Physiol. 274, H663-H671 (1998).
33. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46, 149-168 (2001). An authoritative review of the effect on drug uptake of high IFP in tumours.
34. Baluk, P. et al. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163, 1801-1815 (2003).
35. Abramsson, A. et al. Analysis of mural cell recruitment to tumor vessels. Circulation 105, 112-117 (2002).
36. Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985-1000 (2002).
37. Griffon-Etienne, G. et al. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 59, 3776-3782 (1999).
38. Padera, T. P. et al. Pathology: cancer cells compress intratumour vessels. Nature 427, 695 (2004).
39. Boucher Y. et al. Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc. Res. 50, 175-182 (1995).
40. Dvorak, H. F. et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029-1039 (1995).
41. Stohrer, M. et al. Oncotic pressure in solid tumors is elevated. Cancer Res. 60, 4251-4255 (2000).
42. Alitalo, K. et al. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227 (2002).
43. Padera, T. P. et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883-1886 (2002).
44. Leu, A. J. et al. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 60, 4324-4327 (2000).
45. Boucher, Y. et al. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 52, 5110-5114 (1992).
46. Gabbiani, G. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200, 500-503 (2003).
47. Netti, P. A. et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl Acad. Sci. USA 95, 3137-3142 (1999).
48. Lee, C. G. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565-5570 (2000).
49. Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004). Reports that vessel normalization after VEGF-antagonist treatment induces favourable transvascular hydrostatic pressure gradient in tumours.
50. Wildiers, H. et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88, 1979-1986 (2003).
51. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145-147 (2004). Describes the first analysis of the effect of a VEGF antagonist on tumour vasculature and IFP in patients.
52. Inai, T. et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165, 35-52 (2004).
53. Pietras, K. et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61, 2929-2934 (2001).
54. Pietras, K. et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62, 5476-5484 (2002). Demonstrates that PDGF antagonists lower tumour IFP, as well as increase drug uptake and treatment efficiency in preclinical models.
55. Pietras, K. et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 9, 3779-3787 (2003).
56. Pietras, K. Increasing tumor uptake of drugs with imatinib. Semin. Oncol. 31, 18-23 (2004).
57. Lindahl, P. et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242-245 (1997).
58. Abramsson, A. et al. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest 112, 1142-11451 (2003).
59. Guo, P. et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162, 1083-1093 (2003).
60. Furuhashi, M. et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res. 64, 2725-2733 (2004).
61. Lammerts, E. et al. Interference with TGF-β1 and -β3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int. J. Cancer 102, 453-462 (2002).
62. Jacobson, A. et al. Hyaluronan content in experimental carcinoma is not correlated to interstitial fluid pressure. Biochem. Biophys. Res. Commun. 305, 1017-1023 (2003).
63. Eikenes, L. et al. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 64, 4768-4773 (2004).
64. Kristensen, C. A. et al. Reduction of interstitial fluid pressure after TNF-α treatment of three human melanoma xenografts. Br. J. Cancer 74, 533-536 (1996).
65. Cumis, F. et al. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110, 475-482 (2002).
66. Brekken, C. et al. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res. 20, 3513-3519 (2000).
67. Brekken, C. et al. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res. 20, 3503-3512 (2000).
68. Brekken, C. et al. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett. 131, 65-70 (1998).
69. Kristjansen, P. E. G. et al. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res. 53, 4764-4766 (1993).
70. Emerich, D. F. et al. Bradykinin modulation of tumor vasculature: II. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J. Pharmacol. Exp. Ther. 296, 632-641 (2001).
71. Lee, I. et al. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res. 52, 3237-3240 (1992).
72. 51Cr-EDTA. Int. J. Cancer 86, 636-643 (2000).
73. 1 lowers tumour IFP and increases treatment efficiency in preclinical models.
74. Thurston, G. et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nature Med. 6, 460-463 (2000).
75. Kristensen, C. A. et al. Reduction of interstitial fluid pressure after TNF-α treatment of three human melanoma xenografts. Br. J. Cancer 74, 533-536 (1996).